Abbreviations
ALL
AML
CAREX
CDC
CLL
CML
COMWEL
DDREF
EEOICPA
ERR
IACIA
IARC
ILO
KOSHA
NDR
NDT
NSSC
NTP
PC
Background
Review
Occupational exposure in Korea
Table 1
Radiation carcinogenesis
Table 2
Organ site | Selected key studies |
---|---|
Stomach | Boice et al. (1988) [42], Mattsson et al. (1997) [43], Carr et al. |
Colon | (2002) [44], Preston et al. (2003, 2007) [45, 46] |
Lung | Darby et al. (1994) [47], Preston et al. (2003, 2007) [45, 46] |
Basal cell skin carcinoma |
Weiss et al. (1994) [48], Carr et al. (2002) [44], Gilbert et al. (2003) [49], Preston et al. (2003, 2007) [45, 46] Schneider et al. (1985) [50], Ron et al. (1991, 1998) [51, 52], Little et al. (1997) [53], Shore et al. (2002)[54], Preston et al. (2007) [46] |
Female breast | Howe & McLaughlin (1996) [55], Preston et al. (2002, 2003, 2007) [45, 46, 56] |
Thyroid | Lundell et al. (1994) [57], Lindberg et al. (1995) [58], Ron et al. (1995) [59], Preston et al. (2007) [46] |
Leukemia, excluding CLL | Little et al. (1999) [60], Travis et al. (2000) [61], Preston et al. (2003, 2004) [45, 62], Muirhead et al. (2009) [63] |
Review of epidemiological studies of cancer risk
Atomic bomb survivors and the Chernobyl accident
Occupational exposure in radiation workers
Table 3
Mean | Number of event cases | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Country | Study | Cohort size | Exposure period | Follow-up period | cumulative dose (mSv) | Person years | Types of events | ERR (95% CI) | SMR or SIR (95% CI) | |
15-country | Cardis et al. (2007) [23] | 407,391 | 1943-2000 | 1943-2000 | 19.4 | 5,192,710 | Mortality |
5,024 4,820 |
0.97 b(0.27, 1.8)c 0.58 b (-0.1, 1.39) |
a1.03 (0.65, 1.53) |
Korea | aAhn et al. (2008) [64] | 79,679 |
1984-2004 1984-2004 |
1992-2004 1989-2005 |
6.1 6.1 |
633,159 415,298 |
Mortality Morbidity |
256 564 |
7.2 b(-5, 21) 2.6 (-4, 10)b |
0.73 (0.64, 0.82) |
Jeong et al. (2010) [65] | 8,429 | 1978-2005 | 1992-2005 | 19.86 | 63,503 | Incidence | 96 | 2.06 (-191, 9) | 1.06 (0.86, 1.29) | |
U.K. | Muirhead et al. (2009) [63] | 174,541 | 1946-2001 | 1965-2001 | 24.9 | 3,900,000 |
Mortality Incidence |
7,455 10,855 |
0.28 (-0.03, 0.62) 0.27 (0.00, 0.56) | 0.84 (0.82, 0.86) |
U.S. | Howe et al. (2004) [66] | 53,698 | Mid-1960s | 1979-1997 | 25.7 | 698,051 | Mortality | 368 | 0.51 (-2.01, 4.64) | 0.65 (0.59, 0.72) |
Canada | Zablotska et al. (2014) [67] | 45,316 | 1951-1994 | 1956-1994 | 21.64 | 613,648 | Mortality | 468 |
1.2 (-0.73, 4.33) |
0.72 (0.66, 0.78) |
France | Flamant et al. (2013) [30] | 59,021 | 1950-2004 | 1968-2004 | 16.1 | 1,467,611 | Mortality | 2,312 |
0.34 b(-0.56, 1.38) |
- |
Germany | Merzenich et al. (2014) [68] | 8,972 | 1966-2008 | 1991-2008 | 29.5 | 130,737 | Mortality | 119 | - | 0.63 (0.5, 0.8) |
Japan | Akiba et al. (2012) [28] | 200,583 | 1977-2002 | 1991-2002 | 12.2 | 1,373,000 | Mortality | 2,636 | 1.26 (-0.27, 3) | - |
Russia | Shilnikova et al. (2003) [25] | 21,557 | 1948-1997 | 1948-1997 | 810 mGy | 720,000 | Mortality | 1,730 |
0.15 b(0.09, 0.2) |
- |
Hunter et al. (2013) [26] | 22,366 | 1948-2004 | 1948-2004 | 510 mGy | 535,932 | Incidence | 1,447 | 0.07 (0.01, 0.15) | - |
Table 4
Mean | Number of event cases | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Country | Study | Cohort size |
Exposure period |
Follow-up period |
cumulative dose (mSv) |
Person years |
Types of events |
ERR (95% CI) |
SMR or SIR (95% CI) | |
15-country | Cardis et al. (2007) [23] | 407,391 | 1943-2000 | 1943-2000 | 19.4 | 5,192,710 | Mortality | 196 |
1.93 b(<0, 7.14) |
- |
3-country (INWORKS) |
Leuraud et al. (2015) [24] | 308,297 | 1943-2005 | 1944-2005 | 15.9mGy | 8,220,000 | Mortality | 531 | 2.96 (1.17, 5.21) | - |
Korea | aAhn et al. (2008) [64] | 79,679 |
1984-2004 1984-2004 |
1992-2004 1989-2005 |
6.1 6.1 |
633.159 415,298 |
Mortality Morbidity |
9 14 |
16.8 b(-34, 149) 15.8 b(-31, 108) |
0.59 (0.28, 1.06) |
Jeong et al. (2010) [65] | 8,429 | 1978-2005 | 1992-2005 | 19.86 | 63,503 | Incidence | 3 | NC | 1.34 (0.27, 3.92) | |
U.K. | Muirhead et al. (2009) [63] | 174,541 | 1946-2001 | 1965-2001 | 24.9 | 3,900,000 |
Mortality Incidence |
198 234 |
1.71 (-0.17, 4.92) 1.78 (-0.06, 4.99) | 0.89 (0.76, 1.03) |
U.S. | Howe et al. (2004) [66] | 53,698 | Mid-1960s | 1979-1997 | 25.7 | 698,051 | Mortality | 26 | 5.67 (-2.56, 30.4) |
a 1.07 (0.71, 1.53) |
Canada | Zablotska et al. (2014) [67] | 45,316 | 1951-1994 | 1956-1994 | 21.64 | 613,648 | Mortality | 17 | 9.79 (<-1.49, 107) | 0.78 (0.45, 1.25) |
France | Flamant et al. (2013) [30] | 59,021 | 1950-2004 | 1968-2004 | 16.1 | 1,467,611 | Mortality | 60 |
3.96 b(<0, 16.82) |
- |
Germany | Merzenich et al. (2014) [68] | 8,972 | 1966-2008 | 1991-2008 | 29.5 | 130,737 | Mortality | 7 | - | 1.19 (0.41, 2.75) |
aJapan | Akiba et al. (2012) [28] | 200,583 | 1977-2002 | 1991-2002 | 12.2 | 1,373,000 | Mortality | 80 | -1.93 (-6.12, 8.57) | - |
Russia | Shilnikova et al. (2003) [25] | 21,557 | 1948-1997 | 1948-1997 | 810 mGy | 720,000 | Mortality | 66 |
1 b(0.5, 2) |
- |
Diagnosed cases of radiation-related occupational cancer in Korea
Table 5
Considerations in the recognition criteria for occupational cancer
Recognition criteria in Korea
Table 6
Cohort (patients or workers) | Study | Events |
Cohort size |
Number of events | Risk |
---|---|---|---|---|---|
Ankylosing spondylitis | Weiss et al. (1995) [69] | Mortality | 15,577 | 7 | RR=1.44 (95% CI: 0.62, 2.79) |
Benign locomotor lesions | Damber et al. (1995) [70] | Incidence | 20,024 | 50 | SIR=1.07 (95% CI: 0.80, 1.41) |
Benign gynecological disease | Inskip et al. (1993) [71] | Mortality | 12,955 | 21 | RR=1.1 (90% CI: 0.5, 3.0) |
Breast cancer | Curtis et al. (1989) [72] | Incidence | 22,753 | 10 | RR=1.84 (90% CI: 0.5, 6.7) |
Uterine corpus cancer | Curtis et al. (1994) [73] | Incidence | 110,000 | 54 | RR=0.90 (95% CI: 0.4, 1.9) |
International Radiation | Boice et al. (1988) [42] | OR=1.03 (90% CI: 0.3, 3.9) | |||
Study of Cervical Cancer Patients | Incidence | 11,030 | 52 | ||
Chernobyl liquidators | Romanenko et al. (2008) [74] | Incidence | 110,645 | 39 | ERR/Sv=4.09 (95% CI: <0, 14.41) |
Chernobyl liquidators | Kesminiene et al. (2008) [20] | Incidence | 146,000 | 21 | ERR/Sv=4.7 (90% CI: -®, 76.1) |
France nuclear workers | Flamant et al. (2013) [30] | Mortality | 59,021 | 18 | ERR/Sv=-1.36 (90% CI: <0, 14.94) |
IARC 15-country nuclear workers |
Cardis et al. (2007) [23] | Mortality | 407,391 | 47 | ERR/Sv=-1.0 (90% CI: -5.0, 3.7) |
U.K. NRRW |
Muirhead et al. (2009) [63] |
Mortality | 174,541 | 69 | ERR/Sv=<-1.92 (90% CI: <-1.92, 1.23) |
Incidence | 174,541 | 128 | ERR/Sv=-0.117 | ||
(90% CI: -1.42, 2.71) | |||||
INWORKS | Leuraud et al. (2015) [24] | Mortality | 308,297 | 138 | ERR/Gy=-1.06 (90% CI: <0, 1.81) |
Recognition criteria in other countries
Table 7
Criteria items | Korea | U.K. | U.S. a | France |
---|---|---|---|---|
Eligible cancer sites | Liver (without cirrhosis or hepatitis virus), Thyroid, Ovary, Brain, Multiple myeloma, Colon, Bladder, Non-Hodgkin lymphoma, Esophagus, Kidney, Female breast, Stomach, Pancreas, Salivary gland, Lung, Skin, Leukemia (except CLL) | Bladder, Bone, Brain and central nervous system, Female breast, Colon, Leukemia (except CLL) , Liver, Esophagus, Respiratory/Lung, Prostate, Ovary, Skin (non-melanoma), Uterus, Thyroid, Other tissues | Leukemia with or without CLL, Lymphomas (except Hodgkin lymphomas), Multiple myeloma, Thyroid, Breast, Ovary, Stomach, Lung, Colon, Liver, Bladder, Esophagus, Pancreas, Bone, Salivary gland, Kidney, Brain and central nervous system, Pharynx, Small intestine, Biliary tract and gall bladder, Skin, Rectum, Larynx, Prostate, Pharynx | Leukemia, Primary lung (due to inhalation), Bone sarcoma |
Exposure period | - | - | Employed at least 1 year -Uranium miner: >40 months | - |
Latency period (since first exposure) | Cancer (except leukemia): 5 years Leukemia (except CLL): 2 years | - | Leukemia (except CLL): 2 years Others: 5 years | - |
Occurrence period (after exposure) | Within 20 years | - | Bone cancer: within 30 years Leukemia: any time Others: >5 years | Leukemia and lung cancer: within 30 years Bone sarcoma: within 50 years |
PC (Probability of causation) or degree of disability | Cancer (except leukemia): >50% Leukemia (except CLL): >33% | >20% (Compensated at different rates according to the PC and >50% for full compensation) | >50% (upper 99% confidence level) | Degree of disability: >25% |
Reference | Notification (No. 2014-78) of the NSSC | Occupational safety and health series 73 [41], Compensation scheme for radiation-linked diseases [75] | Occupational safety and health series 73 [41], Energy employees occupational illness compensation program [76], electronic code of federal regulations [77], radiation exposure compensation Act [78], | Occupational safety and health series 73 [41] |